Cigna's decision to drop coverage for popular GLP-1 weight-loss drugs like Wegovy and Zepbound for its employees signals a potential shift in employer-sponsored healthcare. This policy change could drive significant demand toward affordable direct-to-consumer telehealth platforms and alternative digital weight management programs.
Published on June 3
Cigna's decision to drop GLP-1 coverage for its own employees could be the first domino to fall across US employer healthcare. When millions of patients lose access to high-cost drugs overnight, the money has to go somewhere.
Direct-to-consumer platforms and digital health companies are already set up to offer affordable, out-of-pocket weight management alternatives. This isn't a future trend โ the infrastructure is already there and the demand is arriving now.
Professional analysts have handpicked every stock in this group based on their direct exposure to the growing GLP-1 insurance gap. This is the kind of targeted, event-driven opportunity that doesn't come around often.
When a major insurer like Cigna stops covering popular weight-loss drugs, millions of people are left searching for affordable alternatives. That creates a real opportunity for telehealth platforms, digital wellness programmes, and compounding pharmacies that offer out-of-pocket solutions. This group targets the companies best placed to capture that redirected demand as employer-sponsored coverage tightens.
This is a tactical growth theme tied to a specific and evolving policy shift in US healthcare. The stocks here span telehealth providers, nutrition companies, digital therapeutics, and health data firms. Because the theme is driven by ongoing corporate cost-cutting and healthcare policy changes, it carries both opportunity and uncertainty โ making it worth watching closely.
These stocks were handpicked by professional analysts based on their direct exposure to the GLP-1 coverage gap. Each one either operates in the direct-to-consumer healthcare space, offers an alternative weight management solution, or stands to benefit from shifts in employer-sponsored health benefit programmes. Nothing here was chosen at random โ every pick has a clear, reasoned connection to this theme.
This basket's total market capitalisation is $1.35T and is heavily weighted towards a few large-cap stocks that anchor its profile.
HIMS: $6.37B
TDOC: $1.36B
LLY: $1.00T
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
+5
Here are a few of the assets in this group. Create an account to unlock the full list.
TELADOC HEALTH INC
TDOC
Current Price
$6.18
Teladoc Health provides enterprise and direct-to-consumer virtual healthcare services that are well-positioned to capture patients seeking accessible ...
Teladoc Health provides enterprise and direct-to-consumer virtual healthcare services that are well-positioned to capture patients seeking accessible weight management alternatives.
Eli Lilly & Co
LLY
Current Price
$1,240.36
Eli Lilly manufactures Zepbound and operates a direct-to-patient digital health platform to maintain patient access amid tightening insurance coverage...
Eli Lilly manufactures Zepbound and operates a direct-to-patient digital health platform to maintain patient access amid tightening insurance coverage.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
On average, analysts expect assets in this group to grow 181.15% over the next year.
9 of 15 assets in this group are rated Buy by professional analysts.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+181.15%
